hormone producing tumor Neuroendocrine tumor
Conditions
Interventions
[68Ga]-Dotatate
Lanreotide
Neuroendocrine tumor
Sponsors
Antoni van Leeuwenhoek Ziekenhuis
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - >=18 years old - Histologically confirmed low and intermediate grade NET - Metastatic or unresectable disease - Measurable disease on [68Ga]-DOTATATE PET-scan - WHO performance status less than 2 - Life expectancy more than 3 months - Long-acting lanreotide treatment for at least 4 months
Exclusion criteria
Exclusion criteria: - Pregnant or breast-feeding - Claustrophobic
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To visualize and quantify the difference in somatostatin receptor occupancy directly before and after lanreotide injection. | — |
Secondary
| Measure | Time frame |
|---|---|
| a. To assess a correlation between tumor [68Ga]-DOTATATE uptake and size in relation to lanreotide binding. b. To assess differences in [Ga68]-DOTATATE uptake and behavior (reaction to lanreotide) between different metastasis in 1 patient. c. To assess the differences in uptake in normal tissue (thyroid, spleen, liver etc.) before and after lanreotide. d. To assess the correlation between clinical symptoms, receptor occupancy, and tumor markers. | — |
Countries
The Netherlands
Outcome results
None listed